IL-6 (pg/ml) | ||||
Intention-to-treat analysis | ||||
Baseline (64 vs. 62) | 2.84 (2.57) | 2.56 (2.49) | 0.28 (−0.61 to 1.17) | 0.900 |
12-week (45 vs. 41) | 2.40 (1.78) | 2.13 (1.45) | 0.27 (−0.43 to 0.97) | 0.997 |
24-week (29 vs. 26) | 2.03 (2.06) | 2.00 (1.87) | 0.03 (−1.04 to 1.10) | 0.413 |
Per-protocol analysis | ||||
Baseline (45 vs. 44) | 2.23 (2.06) | 2.19 (2.20) | 0.04 (−0.85 to 0.94) | 0.820 |
12-week (42 vs. 37) | 2.36 (1.79) | 2.12 (1.49) | 0.24 (−0.50 to 0.99) | 0.978 |
24-week (27 vs. 23) | 2.05 (2.12) | 1.96 (1.99) | 0.09 (−1.09 to 1.26) | 0.505 |
IL-12 p70 (pg/ml) | ||||
Intention-to-treat analysis | ||||
Baseline (64 vs. 62) | 2.99 (2.28) | 2.95 (3.85) | 0.04 (−1.08 to 1.16) | 0.946 |
12-week (43 vs. 41) | 2.54 (1.96) | 2.24 (1.52) | 0.30 (−0.47 to 1.06) | 0.439 |
24-week (29 vs. 27) | 1.99 (1.30) | 1.85 (1.33) | 0.14 (−0.56 to 0.85) | 0.682 |
Per-protocol analysis | ||||
Baseline (45 vs. 44) | 2.50 (1.98) | 2.46 (2.20) | 0.04 (−0.84 to 0.92) | 0.928 |
12-week (40 vs. 37) | 2.45 (1.83) | 2.31 (1.55) | 0.14 (−0.63 to 0.91) | 0.719 |
24-week (27 vs. 24) | 2.03 (1.32) | 1.81 (1.41) | 0.22 (−0.54 to 0.99) | 0.563 |
ANTI-INFLAMMATORY | ||||
IL-1ra (pg/ml) | ||||
Intention-to-treat analysis | ||||
Baseline (64 vs. 63) | 33.78 (70.89) | 39.10 (71.71) | −5.32 (−30.36 to 19.73) | 0.630 |
12-week (46 vs. 41) | 25.65 (40.57) | 21.43 (35.93) | 4.22 (−12.20 to 20.65) | 0.098 |
24-week (30 vs. 24) | 23.43 (27.18) | 47.52 (76.74) | −24.09 (−57.77 to 9.58) | 0.474 |
Per-protocol analysis | ||||
Baseline (46 vs. 46) | 23.62 (38.27) | 48.42 (81.50) | −24.80 (−51.32 to 1.72) | 0.974 |
12-week (43 vs. 38) | 26.52 (41.75) | 22.21 (37.22) | 4.30 (−13.29 to 21.89) | 0.09 |
24-week (28 vs. 22) | 24.63 (27.74) | 51.16 (79.27) | −26.53 (−26.53 to 62.96) | 0.440 |
IL-4 (pg/ml) | ||||
Intention-to-treat analysis | ||||
Baseline (63 vs. 58) | 12.72 (12.72) | 12.33 (11.89) | 0.38 (−4.06 to 4.83) | 0.865 |
12-week (43 vs. 43) | 9.95 ( 8.46) | 11.07 (11.25) | −1.12 (−5.39 to 3.15) | 0.605 |
24-week (28 vs. 27) | 6.77 ( 6.46) | 7.15 (10.42) | −0.39 (−5.12 to 4.35) | 0.870 |
Per-protocol analysis | ||||
Baseline (45 vs. 43) | 11.47 (10.34) | 11.51 (11.92) | −0.04 (−4.76 to 4.68) | 0.986 |
12-week (40 vs. 39) | 9.53 (8.42) | 11.75 (11.55) | −2.22 (−6.74 to 2.30) | 0.437 |
24-week (26 vs. 24) | 6.73 (6.67) | 7.84 (10.86) | −1.10 (−6.31 to 4.11) | 0.671 |